Eli Lilly (LLY) Stock: $2.3 Billion Ajax Therapeutics Deal Targets Blood Cancer

TLDR

• Eli Lilly is buying privately held Ajax Therapeutics for up to $2.3 billion in cash
• Ajax’s lead drug, AJ1-11095, targets myelofibrosis, a rare blood cancer
• The drug blocks JAK2, a protein that drives several blood cancers, in a novel way
• The deal includes upfront cash plus milestone-based payments
• This is part of Lilly’s broader oncology acquisition push, following deals with Scorpion, Orna, and Kelonia Therapeutics

Eli Lilly (LLY) announced Monday it will acquire privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash. The deal is aimed at bolstering Lilly’s oncology pipeline.

Ajax’s lead asset is AJ1-11095, an experimental once-daily oral drug currently in early-stage clinical trials. It targets myelofibrosis, a rare, chronic blood cancer where scar tissue accumulates in the bone marrow, interfering with normal blood cell production.

The drug works by blocking JAK2, a signaling protein known to drive multiple blood cancers. What makes it different from existing JAK2 inhibitors is the mechanism — it attaches to JAK2 in a distinct way.

Eli Lilly and Company, LLY

That matters because patients on current treatments can stop responding over time. Ajax’s approach is designed to work in those cases, potentially extending the drug’s usefulness beyond what’s already on the market.

Ajax is also developing the drug for polycythemia vera, a condition where the body produces too many red blood cells — another JAK2-driven disease.

The $2.3 billion figure is a ceiling, not a guaranteed sum. Lilly said the total includes an upfront payment and additional milestone payments tied to clinical and regulatory progress.

Lilly’s Oncology Spending Spree

This deal fits a clear pattern. Lilly has been on an active acquisition run in oncology, having already purchased Scorpion Therapeutics, Orna Therapeutics, and Kelonia Therapeutics in recent periods.

Each deal has added something different to the pipeline. Ajax adds a blood cancer angle with a drug that has a differentiated mechanism — exactly the kind of asset Lilly has been hunting.

Scotiabank analyst Louise Chen called the deal a logical fit. She said it “builds on Lilly’s established capabilities in blood cancers and helps expand its future commercial products beyond obesity.”

That last part is worth noting. Lilly’s recent growth has been heavily tied to its GLP-1 obesity and diabetes drugs. The oncology push is a diversification play.

What’s Next for Ajax’s Drug

AJ1-11095 is still early. It’s in Phase 1 testing, meaning there’s a long road ahead before any potential approval.

Myelofibrosis is a disease with real unmet need. Current treatments help manage the condition but don’t work for everyone, and patients can develop resistance to JAK inhibitors already approved for the disease.

If AJ1-11095 performs in later trials, it could address that resistance gap. But that’s still years away from being known.

Lilly’s oncology team will now take the drug forward, bringing the company’s clinical development infrastructure to bear on the program.

The deal is expected to close following standard regulatory review processes. Financial terms beyond the $2.3 billion ceiling were not disclosed.

The post Eli Lilly (LLY) Stock: $2.3 Billion Ajax Therapeutics Deal Targets Blood Cancer appeared first on CoinCentral.